GlassScriptPhysician profile
Chundra Brooks
NPI 1699116624
$6,670.63
in general payments reported to CMS, 2019-2025
28 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $105 · 2022: $205 · 2023: $1,641 · 2024: $2,905 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,481 · Travel and Lodging: $788 · Education: $91.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,480.76 |
| Travel and Lodging | $787.77 |
| Education | $91.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,670.96 | 2021-2025 | |
| Enterra Medical, INC. | $1,096.41 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $440.09 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $385.64 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $378.38 | 2023-2025 | Stelara, Tremfya |
| Intercept Pharmaceuticals, INC. | $327.91 | 2022-2024 | Ocaliva |
| Genzyme Corporation | $315.78 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $299.79 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Madrigal Pharmaceuticals | $275.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $175.43 | 2024-2025 | Tremfya |
| Ardelyx, INC. | $173.21 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $168.19 | 2023-2025 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $138.79 | 2023-2024 | Rebyota |
| Phathom Pharmaceuticals, INC. | $134.45 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $128.00 | 2025 | Livdelzi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $100.62 | 2023-2024 | Zeposia |
| Pfizer INC. | $97.59 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $79.15 | 2023 | Zeposia |
| Merck Sharp & Dohme LLC | $59.87 | 2023 | Dificid, Lynparza, Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $43.61 | 2022-2023 | |
| Braintree Laboratories, INC. | $38.64 | 2025 | Suflave, Sutab |
| Lilly USA, LLC | $27.78 | 2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $23.49 | 2025 | Iqirvo |
| Glaxosmithkline, LLC. | $20.75 | 2023 | Jemperli, Zejula |
| Boston Scientific Corporation | $20.66 | 2023 | Exalt Model D |
| Ironwood Pharmaceuticals, INC | $20.51 | 2024 | |
| Olympus America INC. | $14.78 | 2021 | |
| Evoke Pharma, INC. | $14.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chundra Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.